BRCA2 and triple-negative breast carcinoma: Moreover, the loss of ARH3 increased PARPi resistance in triple-negative breast cancer (TNBC) SUM149PT (BRCA1 mutant, BRCA2-WT) and SUM159PT (BRCA1/2-WT) cells (Figures 3H, S3K, and S3L).